Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2008-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2008.08.040PMID 18782666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.

  2008cited by this paper
• Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.

  2008cited by this paper
• Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.

  2008cited by this paper
• New fluoro-diphenylchalcogen derivatives to explore the serotonin transporter by PET.

  2007cited by this paper
• Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.

  2006cited by this paper
• Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

  2005cited by this paper
• A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

  1997cited by this paper
• Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine.

  1994cited by this paper
• Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions.

  1994cited by this paper

• An interim internal Threshold of Toxicologic Concern (iTTC) for chemicals in consumer products, with support from an automated assessment of ToxCast™ dose response data.

  2020cites this paper
• THE EFFECTIVE APPLICATION OF METABOLITE PROFILING IN DRUG DESIGN AND DISCOVERY.

  2020cites this paper
• The Role of Biotransformation Studies in Reducing Drug Attrition

  2013cites this paper
• Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays

  2013cites this paper
• Combining Structure‐Based Pharmacophore and In Silico Approaches to Discover Novel Selective Serotonin Reuptake Inhibitors

  2013cites this paper
• Metabolism-guided drug design

  2013cites this paper
• Metabolic Stability and Analogue‐Based Drug Discovery

  2012cites this paper
• 4-Cyanophenols bearing metabolically robust substituents

  2011cites this paper
• Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

  2010cites this paper
• Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.

  2009cites this paper
• Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.

  2009cites this paper